Wild: I never thought you were a basher, I just didn't follow, now I do.
As to the buyout thought, with game changers, if successful, like Z-944, and more so Z-160, it could very well set off a bidding war between 2 or more suitors. As I have said many times if a buyout happened we would be the ones getting it in the shorts. There is usually one reason a large firm goes after a smaller one. The targeted firm has a blockbuster situation in the market place. If management sold out, and that is the only way it can happen due to the 75% requirement, I would PO'ed to no end. To have stuck with this as long as I have and then watch helplessly as an interloper picked the low hanging fruit would not make it a good day.
Jim Long and calm
Jim, again, I am not basher. I just think of an early exit. In all these years, Synavive stopped development, FOV1101 held indefinitely, Z944 P2 postponed. Now there is no news before Oct deadline. I hope Z160 P2 result will be very positvie, so we long can all be rewarded.But Z160 P2 result may just like Synavive. So buyout now is not bad choice, we can use the money to do other investment. Best wishes!
The agreement for a Pfizer acquisition of Icagen was announced on July 20, a cash deal valued at $6 per share. Icagen shares traded at around $2.40 per share until Pfizer's interest in acquiring Icagen became public in June.
How much big pharma will offer for Zalicus buyout?
My view: If Z944 is a go, we'll partner it soon
If Z944 is a bust, then Z is a one man pony--Z160...and that could make it an early buyout or takeover target, quick and easy, with only one product to price in.
Either way, the price is going up...lol